CARDIAC Na^+^ HANDLING
======================

In cardiac myocytes, intracellular Na^+^ concentration (\[Na^+^\]~i~) is a key modulator of Ca^2+^ cycling, contractility and metabolism, and is controlled by the balance between Na^+^ influx and extrusion (**Figure [1](#F1){ref-type="fig"}**). The major contributors to Na^+^ entry during the cardiac cycle are the Na^+^/Ca^2+^ exchanger (NCX), the voltage-dependent Na^+^ channel (Na~V~), and the Na^+^/H^+^ exchanger (NHE) with relative contributions of NCX \> Na~V~ \> NHE (see **Figure [1](#F1){ref-type="fig"}**). Smaller amounts of Na^+^ also enter the cell via the Na^+^/HCO~3~^-^ and the Na^+^/K^+^/2Cl^-^ cotransporters, and the Na^+^/Mg^2+^ exchanger. Na^+^ efflux is controlled primarily through the Na^+^/K^+^ ATPase (NKA) that keeps \[Na^+^\]~i~ constant at steady-state \[reviewed in ([@B22])\].

![**Schematic showing the main processes regulating \[Na^+^\]~**i**~ and \[Ca^**2**+^\]~**i**~ homeostasis in cardiac myocytes and the mechanisms by which an increase in \[Na^+^\]~**i**~ affects \[Ca^**2**+^\]~**i**~, contractility, and metabolism.** Upon cardiac myocyte electrical excitation, Na~V~ opening initiates the AP upstroke and allows Na^+^ entry (limited to 6--15 μmol/L by rapid inactivation). E~m~ depolarization causes LTCC openings and consequent Ca^2+^-induced SR Ca^2+^ release, which triggers contraction. During relaxation, Ca^2+^ is reuptaken into the SR by SERCA, and extruded out of the cytosol through NCX, which extrudes the \~10 μmol/L Ca^2+^ that enters via LTCCs and leads to an increase in \[Na^+^\]~i~ by \~32 μmol/L during each AP. NHE brings in \~2 μmol/L Na^+^ at physiological intracellular pH (\~16 μmol/L during intracellular acidosis). The Na^+^/HCO~3~^-^ and the Na^+^/K^+^/2Cl^-^ cotransporters, and the Na^+^/Mg^2+^ exchanger contribute minimally to the total Na^+^ entry (\~40--45 μmol/L), which is then extruded by NKA \[reviewed in ([@B22])\].](fphar-05-00041-g001){#F1}

An integrative approach to cellular Na^+^ handling is critical to understand how these pathways interact spatially and temporally to affect cardiac cell function. Indeed, compelling evidence has accumulated that local \[Ca^2+^\]~i~ and \[Na^+^\]~i~ gradients exist close to the cell membrane ([@B15]) that depend on the spatial localization of specific Na^+^ and Ca^2+^ handling proteins and their isoforms (**Figure [1](#F1){ref-type="fig"}**). For example, NKA-α2 is more concentrated at the t-tubules (whereas NKA-α1 is homogenously distributed), and this could be important in regulating local cleft \[Na^+^\]~i~ and \[Ca^2+^\]~i~ ([@B8]; [@B21]). NCX is concentrated at the t-tubules, but only a small NCX fraction colocalizes with proteins specific to the dyadic cleft \[i.e., L-type Ca^2+^ channels (LTCCs) and ryanodine receptors (RyRs; [@B33])\]. Nevertheless, functional data indicate that NCX senses an early and high rise in local vs. bulk \[Ca^2+^\]~i~ ([@B72]) and Ca^2+^ entry via reverse mode NCX can even trigger sarcoplasmic reticulum (SR) Ca^2+^ release ([@B39]). Moreover, a loss-of-function mutation in ankyrin-B results in reduced NKA and NCX protein levels and impaired targeting to the t-tubules, which causes altered Ca^2+^ signaling and after contractions ([@B46]) and can affect local \[Na^+^\], cellular and SR Ca^2+^ cycling ([@B14]), and kinase/phosphatase balance ([@B20]).

Cardiac Na^+^ channel (Na~V~1.5) activity also requires proper sarcolemmal localization. For example, defective membrane targeting by impaired interaction of Na~V~1.5 and ankyrin-G causes Brugada syndrome (BrS; [@B45]). Na~V~1.5 are found roughly homogenously distributed in the t-tubules and external sarcolemma, whereas non-cardiac Na~V~ isoforms (whose role is still poorly understood) are more concentrated at the t-tubules ([@B13]). However, immunofluorescence studies show Na~V~1.5 mostly at the intercalated disks, and it has been proposed that different pools of Na^+^ channels are located in the external sarcolemma vs. intercalated disks, where they interact within different macromolecular complexes and are regulated differently ([@B38]; [@B51]; [@B57]).

Altered Na^+^ homeostasis through the mechanisms described above (and in **Figure [1](#F1){ref-type="fig"}**) contributes to action potential (AP) and \[Ca^2+^\] cycling dysregulation, leading to arrhythmia, metabolic imbalance, remodeling and cell death, and is a hallmark of various cardiac diseases. The search for a common denominator has pointed to the Ca^2+^/calmodulin-dependent protein kinase II (CaMKII). CaMKII is a basophilic serine/threonine kinase that plays critical roles in cardiac physiology and disease (where it is often found hyperactive) through phosphorylation of several Ca^2+^ handling proteins and ion channels (**Figure [1](#F1){ref-type="fig"}**; [@B9]; [@B3]). Na~V~1.5, in particular, has emerged as a principle CaMKII target. Herein, we summarize growing evidence indicating an important role for CaMKII in regulating Na~V~1.5 gating and cardiomyocyte Na^+^ homeostasis, with an emphasis on the important interconnection between Na^+^ and Ca^2+^ handling, and consequences for arrhythmia.

CARDIAC Na^+^ CHANNEL STRUCTURE AND FUNCTION
============================================

The cardiac Na^+^ channel is responsible for the upstroke of the cardiac AP and is a critical determinant of cardiac electrical excitability. The pore forming α-subunit, Na~V~1.5, is composed of four core domains (DI--DIV), each containing six transmembrane segments (S1--S6; \~230 kD; **Figure [2](#F2){ref-type="fig"}**). The positively charged S4 segments serve as the channel voltage sensors and the S5--S6 segments comprise the ion-conducting pore. Upon depolarization, the channel rapidly activates (\<1 ms) producing a large (tens of nA), transient inward Na^+^-current, I~Na~, and then undergoes fast inactivation (within a few ms) through interactions of the well-described DIII--IV linker IFM motif with the pore (similar to N-type inactivation in K^+^ channels). This is followed by poorly understood slower modes of inactivation (hundreds of ms to a few s) that likely involve rearrangements of the pore structure (similar to C-type inactivation in K^+^ channels). Channels that fail to completely inactivate, or close and then reopen, give rise to a persistent, or late Na^+^ current (I~NaL~). Na~V~1.5α forms macromolecular complexes with β-subunits (β1 to β4) and many other accessory and regulatory proteins that modify channel gating \[extensively reviewed by [@B1]; [@B75]\]. The intracellular N- and C-termini and linker loops connecting DI--IV are also all involved in channel gating. In particular, the Na~V~1.5 I--II cytoplasmic linker loop is the subject of extensive post-translational regulation, and this region has received much attention as a hot spot for phosphorylation by CaMKII \[reviewed in ([@B31])\].

![**Clustal sequence alignment of Na~**V**~1.5 I--II loop across indicated species.** Sites are color coded as follows: red font = phosphorylation; green font = methylation; yellow block = basophilic kinase consensus region; green bounding box = missense BrS mutation; blue block = LQTS mutation.](fphar-05-00041-g002){#F2}

PHOSPHORYLATION OF Na~V~1.5 BY CaMKII
=====================================

CaMKII activation has been shown to alter the gating properties of the Na^+^ channel, as summarized in **Table [1](#T1){ref-type="table"}**. Specifically, CaMKII phosphorylation of Na~V~1.5 shifts the voltage dependence of inactivation to negative potentials without affecting channel activation, slows recovery from and enhances entry into slower forms of inactivation, and increases I~NaL~ ([@B69]).

###### 

Na~**V**~1.5 phosphorylation sites, their associated kinases, and biophysical effects.

  Residue                                              Kinase   SSI   I~NaL~   Comments                                                                                            Reference
  ---------------------------------------------------- -------- ----- -------- --------------------------------------------------------------------------------------------------- ------------------------
  S516                                                 CaMKII   ←     ↔                                                                                                            [@B4]
  T594                                                 CaMKII   ←     ↔                                                                                                            [@B4]
  S571                                                 CaMKII   ←     ↑        Basally phosphorylated by MS                                                                        [@B32], [@B36], [@B44]
  S525                                                 PKA      ←     ND       EP effects are indirect; mutant EP studies ND                                                       [@B80]
  S528                                                 PKA      ←     ND       EP effects are indirect; mutant EP studies ND                                                       [@B80]
  S457, S460, S483/4, S497, S510, S524/5, S664, S667   ND       ND    ND       MS identification; basal phosphorylation in untreated mouse heart lysates; responsible kinases ND   [@B44]

EP = electrophysiological; ND = not determined; MS = mass spectrometry.

The Na~V~1.5 I--II linker loop interacts with CaMKII ([@B4]) and contains multiple basophilic kinase consensus sequences. Mass spectrometry analysis of wild type Na~V~1.5 (purified from mouse heart lysates) revealed several sites within this loop that are basally phosphorylated ([@B44]; **Figure [2](#F2){ref-type="fig"}**, red color, and **Table [1](#T1){ref-type="table"}**). [@B32] mutated putative CaMKII consensus sites to non-phosphorylatable alanine residues and determined that CaMKII specifically phosphorylates S571. When expressed in a heterologous expression system, the S571A non-phosphorylatable mutant abolished constitutively active co-expressed CaMKII enhancement of channel inactivation and I~NaL~. On the other hand, phosphomimetic S571E recapitulated CaMKII effects (but still in the presence of constitutively active CaMKII). S571 phosphorylation was increased in murine ([@B65]) and human heart failure (HF) and canine ischemic cardiomyopathy ([@B36]).

Because CaMKII (and other kinases) can phosphorylate non-canonical sequences, we screened the entire Na~V~1.5 I--II loop for CaMKII phosphorylation with an *in vitro* kinase assay system ([@B4]). This assay consisted of a tiled peptide array spanning the entire loop region followed by *in vitro* phosphorylation with recombinant CaMKII and revealed that site S516 was phosphorylated most efficiently by CaMKII ([@B4]). Immobilized peptides containing S483/S484 and S593/T594 were also phosphorylated in this assay at much lower efficiency. It is important to consider peptide conformation may change when a peptide is immobilized or soluble, which can affect kinase access to phospho-acceptor sites ([@B6]). In fact, subsequent studies using soluble peptides showed that T594 but not S483/4 could be phosphorylated, although only at low efficiencies. Furthermore, peptide conformation and kinase binding may be different for the full-length channel, thus affecting its ability to be phosphorylated. Therefore, additional phosphorylation studies using full-length Na~V~1.5 are needed.

Wild type or non-phosphorylatable mutant channels (S516A, T594A, S571A) were coexpressed with CaMKIIδC in HEK293 cells and voltage-clamped under pipette conditions to acutely activate CaMKII (with Ca^2+^ and calmodulin), with or without CaMKII inhibition \[by autocamtide-2 inhibitory peptide (AIP); [@B4]\]. CaMKII shifted steady-state inactivation (SSI) to hyperpolarizing potentials and increased entry into inactivation, and this was blocked with AIP or by mutating these sites to non-phosphorylatable alanine. Phosphomimetic S516E and T594E mutants recapitulated the hyperpolarizing shift in SSI even in the absence of CaMKII and presence of AIP. In our hands, however, S571E phosphomimetic mutants showed no statistically significant negative shift in SSI. Moreover, we observed no enhancement of late I~NaL~ in any of the mutants tested, but we did not coexpress β-subunits, which some have indicated to be important for I~NaL~ ([@B43]). Importantly, the phosphorylation status of S516 and T594 in native myocytes is yet to be determined, and more studies are needed to determine the relative contribution of these sites to specific channel gating properties.

FUNCTIONAL CONSEQUENCES OF I--II LOOP PHOSPHORYLATION: INSIGHT FROM INHERITED MUTATIONS
=======================================================================================

Structure-function studies of *SCN5A* channelopathies/inherited mutations may further an understanding of the functional consequences of Na~V~1.5 phosphorylation. CaMKII-dependent alterations of Na~V~1.5 gating are remarkably similar to those caused by the Na~V~1.5 mutation 1795insD ([@B10]), which is associated to patients with mixed long QT syndrome (LQTS) and BrS phenotypes. DelK1500 is another overlap mutation that causes both loss and gain of function channel effects and is functionally similar to the effects of CaMKII phosphorylation on Na~V~1.5 ([@B30]). Experiments and simulations have shown how the heart rate acts as a switch imparting LQTS or BrS phenotypes to the same genotype ([@B66]; [@B16]), and we have hypothesized a similar scenario for CaMKII effects ([@B29]). However, 1795insD and delK1500 are present on the Na~V~1.5 C-terminus and III--IV loop respectively, making structural correlation with CaMKII phosphorylation on the I--II loop difficult. To date, no overlap mutations have been identified anywhere within the I--II loop ([@B54]).

While no overlap mutations are present, several mutations or polymorphisms have been identified within the I--II loop phosphorylation hot spot through studies of LQTS and BrS patient cohorts. Examination of these mutations may be useful in dissecting out the structure-function relationship of kinase phosphorylation within this region. More than 30 putative BrS mutations have been identified in the I--II loop from residues 416--711 ([@B35]; **Figure [2](#F2){ref-type="fig"}**). Unfortunately, not all of these have been followed up with functional studies. One mutation, L567Q, was identified in a family exhibiting BrS and sudden infant death syndrome ([@B53]). When expressed heterologously, the mutant Na~V~1.5 channel displayed a negative shift in inactivation and enhanced entry into inactivation that was not dependent on coexpression of β-subunits ([@B71]). Another mutation, T512I, was identified in a patient exhibiting cardiac conduction disease, and resulted in hyperpolarizing shifts in SSI and activation and enhanced slow inactivation ([@B68]). Not only is this mutation juxtaposed to one of the known CaMKII phosphorylation consensus regions identified at R513 and phosphorylated at S516 \[see **Figure [2](#F2){ref-type="fig"}** and ([@B4])\], it also functionally mirrors the enhanced inactivation conferred by CaMKII phosphorylation at S516. Furthermore, PKA phosphorylation of nearby S525 and S528 ([@B49]) has been previously described to similarly shift the voltage dependence of inactivation to negative potentials ([@B80]). Thus, phosphorylation by either PKA (S525, S528) or CaMKII (S516) within a short \~10 amino acid stretch results in similar channel biophysics compared with the loss of function BrS mutation identified at T512. Moreover, a recent proteomics study demonstrated that residues R513 and R526 within this same region can be methylated, but the functional effect of this post-translational modification is unknown ([@B7]). Another mutation, G514C, was identified in a family with cardiac conduction disease. Under voltage clamp, this mutation displayed a mixed biophysical phenotype of destabilized inactivation and decreased activation ([@B62]). These observations cement the importance of this short region in voltage-dependent inactivation of the channel.

CaMKII-dependent phosphorylation at S571 has been shown to result in both loss and gain of channel function ([@B32]). The functional effects of a negative charge at this site from CaMKII phosphorylation were suggested to phenocopy the adjacent inherited LQTS charge mutations at A572D and Q573E ([@B36]). Although A572D was initially identified as a causative LQTS mutation ([@B64]), a subsequent study showed that this mutation is actually a benign variant and does not cause LQTS in and of itself ([@B63]). Similarly, a mutation identified in a LQTS patient at 619 was also attributed to an observed LQTS phenotype in this patient. This L619F mutation was found to induce I~NaL~ when expressed in a heterologous expression system ([@B74]). However, a LQTS screening study from the Roden group failed to detect any late I~NaL~ (or gating changes) from L618F mutants expressed in heterologous cells and concluded this mutation is also a benign variant ([@B77]). Indeed, mutations within the Na~V~1.5 I--II loop have poor disease predictive value stemming from the high incidence of benign variants within this region ([@B34]).

Thus, a clear and consistent role for the Na~V~1.5 I--II loop in loss of function inactivation gating emerges from studies of kinase phosphorylation (both CaMKII and PKA) and inherited mutations within this hotspot. There is less evidence for this loop region mediating I~NaL~ effects, with different groups providing contradictory results. It remains to be determined whether other unidentified CaMKII phospho-sites exist on other intracellular loops of Na~V~1.5 that may mediate (contribute to) enhancement of I~NaL~ (e.g., the C-terminus ([@B18]) or III--IV loop where overlap mutations have been identified). It is also conceivable that I~NaL~ enhancement in pathological conditions could be due to an increase in neuronal Na^+^ channel isoforms with higher fractional I~NaL~ ([@B76]; [@B11]; [@B78]; [@B65]). Alternatively, the effect of CaMKII to augment I~NaL~ may require accessory proteins not present in heterologous cell systems \[such as regulatory β subunits ([@B43])\]. Indeed, this emphasizes the need for studies of these phosphorylation sites in native adult cardiomyocytes. Human induced pluripotent stem cells may also be used as suitable models, as has been done for some inherited mutations, such as 1795insD ([@B19]).

Enhanced inactivation and consequent reduction in channel availability due to CaMKII phosphorylation is expected to contribute to re-entrant arrhythmias from slowed conduction and enhanced dispersion of repolarization \[as we have extensively reviewed previously ([@B31])\]. On the other hand, CaMKII enhancement of I~NaL~, while not as well understood mechanistically, can also lead to arrhythmias arising from prolonged AP duration (APD) that makes the cell more vulnerable to triggered activity \[via early after-depolarizations (EADs)\]. EADs are favored by conditions leading to prolongation of the AP plateau within a voltage range permitting recovery from inactivation and reactivation of LTCC, or can be the consequence of SR Ca^2+^ release and consequent augmentation of NCX current. A novel and unique mechanism underlying phase 3 EADs in ventricular myocytes from CaMKIIδC overexpressing mice has been recently described ([@B24]), which involves isoproterenol-induced exaggerated Ca^2+^ release, increased inward NCX current, and non-equilibrium reactivation of fast I~Na~.

I~NaL~ AND CELLULAR Na^+^ LOADING IN HF
=======================================

In addition to directly affecting myocytes electrical stability, I~Na~ is a major pathway of Na^+^ influx into cardiac myocytes, although NCX plays the most dominant role both at rest and in contracting cells \[see **Figure [1](#F1){ref-type="fig"}** and ([@B22])\]. In normal myocytes I~NaL~ contribution to Na^+^ entry is limited, but when I~NaL~ is enhanced in diseased conditions (such as cardiac hypertrophy and HF) it carries as much Na^+^ as the fast I~Na~ transient, thus increasing total cellular Na^+^ influx during a cardiac cycle and potentially contributing to Na^+^ overload ([@B42]; [@B22]). Indeed, intracellular Na^+^ concentration (\[Na^+^\]~i~) is increased in myocytes from failing hearts compared to non-failing myocytes by 2--6 mM ([@B52]; [@B59]), but the precise mechanism(s) remains unclear (**Figure [3](#F3){ref-type="fig"}**). It has been suggested that CaMKII and enhanced I~NaL~ contribute to \[Na^+^\]~i~ elevation in HF, as CaMKIIδC overexpressing mice with HF exhibit prominent I~NaL~ and have increased \[Na^+^\]~i~ ([@B69]).

![**CaMKII activation and Na^+^ homeostasis are intimately related in the regulation of cellular Ca^**2**+^, contractility and electrical stability.** With CaMKII hyperactivity, increase in late I~Na~ favors AP prolongation and EADs. Cellular Na^+^ loading increases Ca^2+^, via outward shift in NCX, which further activates CaMKII, fueling a vicious cycle that favors spontaneous SR Ca^2+^ release and predisposes to Ca^2+^-related arrhythmia. Elevated \[Na^+^\]~i~ can also influence ROS production by affecting mitochondrial \[Ca^2+^\]~i~. A less appreciated observation is that high \[Na^+^\]~i~ by causing outward shifts in both NCX and NKA will tend to shorten the AP, as predicted by computational AP models ([@B28], [@B27]). We speculate that the increased \[Na^+^\]~i~ in HF may limit AP prolongation caused by reduced K^+^ channel conductance and increased I~NaL~.](fphar-05-00041-g003){#F3}

While the increase in I~NaL~ may play a role in the observed \[Na^+^\]~i~ loading in these transgenic mice ([@B69]), we demonstrated that CaMKII-dependent enhancement of I~NaL~ is not quantitatively sufficient to account for the \[Na^+^\]~i~ elevation observed in HF ([@B29]; [@B70]; [@B47]; [@B48]). Additionally, in a rabbit model of pressure- and volume-overload-induced HF, [@B23] reported an increased Na^+^ influx resulting primarily from a TTX-sensitive pathway, which accounted for a gain in \[Na^+^\]~i~ of \~3 mM, and was present both in resting and electrically stimulated cells. This supports the existence of a diastolic Na^+^ influx in failing myocytes responsible for \[Na^+^\]~i~ elevation, although it is currently unclear whether this diastolic influx is carried by Na~V~s \[whether they be of cardiac, neuronal, or skeletal muscle isoforms ([@B11]; [@B78])\] or by which gating mechanism. Increases of Na^+^ window and/or background current can potentially contribute to increased Na^+^ influx in failing vs. normal myocytes \[and could be modified by drugs affecting the voltage dependence of Na^+^ channel gating ([@B59])\]. We showed that simulation of an increased sarcolemmal Na^+^ leak current allows recapitulating the \[Na^+^\]~i~ gain seen in HF ([@B70]; [@B47]; [@B48]). [@B5] using the same pressure- and volume-overload rabbit HF model in [@B23] found that increased Na^+^ influx via NHE was the largest contributor to the elevated Na^+^ influx rate and \[Na^+^\]~i~ in paced myocytes. Interestingly, CaMKII activates NHE ([@B67]). Reduced Na^+^ extrusion could also contribute to the observed intracellular Na^+^ gain during HF. Despite reduced expression, NKA function is unchanged in HF ([@B23]; [@B5]), which is possibly due to higher NKA function secondary to reduced relative expression and elevated phosphorylation of phosholemman ([@B12]).

CONSEQUENCES OF Na^+^ LOADING ON EXCITATION-CONTRACTION COUPLING
================================================================

\[Na^+^\]~i~ elevation in HF is expected to limit Ca^2+^ extrusion via forward mode NCX, and could even favor Ca^2+^ entry via reverse mode NCX ([@B73]; **Figures [1](#F1){ref-type="fig"}** and **[3](#F3){ref-type="fig"}**). Slowing Ca^2+^ extrusion via NCX will tend to elevate diastolic \[Ca^2+^\]~i~, thereby contributing to diastolic dysfunction. The slowed \[Ca^2+^\]~i~ decline and elevated diastolic \[Ca^2+^\]~i~ will also tend to increase SR Ca^2+^ content, thus exerting a positive inotropic effect and enhancing contractility. This explains the efficacy of cardiac glycosides in the treatment of congestive HF. These compounds promote inotropy by selectively inhibiting NKA and thereby impairing Na^+^ extrusion and weakening the NCX Ca^2+^ extrusion gradient. However, they are well known for having undesired arrhythmic consequences ([@B2]) by increasing the propensity for spontaneous SR Ca^2+^ release and delayed after-depolarizations (DADs). DADs arise from a transient inward current I~ti~ through forward mode NCX, which is evoked by the sudden increase in \[Ca^2+^\]~i~. It has been recently proposed that CaMKII is mechanistically involved in glycoside-induced arrhythmogenesis, as ouabain increased CaMKII activity, and CaMKII inhibition significantly reduced ouabain-induced spontaneous contractile activity and Ca^2+^ waves ([@B26]). CaMKII overexpression exacerbated ouabain-induced spontaneous contractile activity ([@B26]), possibly by favoring spontaneous SR Ca^2+^ release and DADs, as demonstrated in a recent computational mouse model ([@B48]). Ouabain-induced \[Na^+^\]~i~ loading has also been shown to result in apoptosis ([@B56]), mediated by reverse mode NCX-dependent activation of CaMKII. Thus, CaMKII inhibition may have potential therapeutic benefit during glycoside treatment to prevent arrhythmia and cell death while minimally impacting the positive inotropic effect. Analogously, the Na^+^ channel opener ATX-II induces spontaneous diastolic Ca^2+^ release from the SR and DADs in myocytes ([@B60]) and arrhythmia in Langendorff perfused hearts ([@B79]), which is attenuated with CaMKII or I~NaL~ inhibition.

Our recent model of the failing human ventricular myocyte confirmed that a 20% increase in \[Na^+^\]~i~ in HF compared to control conditions slows forward mode inward NCX (Ca^2+^ extrusion) and enhances reverse mode NCX (Ca^2+^ entry, at the beginning of the AP; [@B47]). This, coupled with AP prolongation due to extensive ionic remodeling in HF (including enhanced I~NaL~), increased diastolic \[Ca^2+^\]~i~ while maintaining adequate SR Ca^2+^ load and Ca^2+^ transient despite reduced SR Ca^2+^-ATPase (SERCA) function. However, \[Na^+^\]~i~-induced Ca^2+^ enhancement, in combination with hyperphosphorylated RyRs, causes diastolic SR Ca^2+^ release, I~ti~, and triggered APs \[**Figure [3](#F3){ref-type="fig"}**, also favored by a more depolarized resting membrane potential (E~m~) in HF, due to decreased I~K1~ and increased background Na^+^ current\]. Simulations showed that by targeting pathological late Na^+^ current and diastolic Na^+^ influx, ranolazine (1) limits \[Na^+^\]~i~ thus restoring normal NCX forward mode that speeds up Ca^2+^ extrusion, (2) shortens APD, thus further limiting Ca^2+^ entry, and (3) hyperpolarizes the E~m~, which elevates the threshold of triggered APs. These simulation results are consistent with recent experimental data in human failing myocytes from hypertrophic cardiomyopathy samples ([@B17]). Similarly, CaMKII-dependent \[Na^+^\]~i~ elevation (normalized by ranolazine) has been associated with diastolic dysfunction and arrhythmias in CaMKIIδC overexpressing mice with HF ([@B61]). Taken together, these observations suggest that limiting \[Na^+^\]~i~ overload may be an appropriate antiarrhythmic therapeutic for the prevention of diastolic tension and arrhythmia triggers driven by \[Ca^2+^\]~i~ loading.

ARRHYTHMOGENIC CaMKII--Na^+^--Ca^2**+**^--CaMKII FEEDBACK
=========================================================

It has been proposed that \[Ca^2+^\]~i~ loading caused by elevated \[Na^+^\]~i~ in HF may positively feed back to further activate CaMKII (and enhance target phosphorylation) thus creating an arrhythmogenic vicious circle. This positive feedback from Na^+^ to Ca^2+^ to CaMKII to Na^+^ has been qualitatively described for Na^+^ loading induced by ATX-II or accompanying a LQT3 mutation associated with increased I~NaL~ ([@B79]). Both of these conditions increased \[Ca^2+^\]~i~, induced CaMKII activation, increased CaMKII-dependent phosphorylation of phosholamban and RyRs, and favored arrhythmias. Although a CaMKII-dependent increase in Na~V~ phosphorylation was not directly confirmed in that study, a \[Ca^2+^\]~i~-dependent increase in I~NaL~ involving both CaMKII and PKC has previously been demonstrated ([@B41]). Accordingly, blockade of I~Na~ or I~NaL~ with TTX or ranolazine reversed all these effects, as did CaMKII inhibition via AIP or KN-93 ([@B79]). Our recently developed mouse myocyte model showed that alterations in Na^+^ handling accompanying transgenic CaMKII overexpression (namely, increase in systolic I~NaL~ and diastolic Na^+^ leak) can increase intracellular Na^+^ gain to initiate Ca^2+^ overload and CaMKII activation. Furthermore, this mechanism proved to be quantitatively sufficient to further disrupt Ca^2+^ (and Na^+^) homeostasis and promote cellular arrhythmias ([@B48]). The simulated effect of Na^+^ loading to fuel CaMKII-Na^+^-Ca^2+^-CaMKII feedback was even more striking when CaMKII was further activated by isoproterenol. This is consistent with the observation that β-adrenergic stimulation of myocytes isolated from mice overexpressing CaMKII ([@B55]) or subjected to TAC-induced HF ([@B65]) increased the number of DADs, which were largely prevented by either ranolazine or AIP ([@B65]).

CONSEQUENCES OF \[Na^+^\]~i~ LOADING ON CARDIAC ENERGETICS
==========================================================

\[Na^+^\]~i~ is also important in regulating cardiac myocyte bioenergetics, by controlling mitochondrial \[Ca^2+^\] via the mitochondrial NCX, and critically regulating the production of mitochondrial reactive oxygen species (ROS, **Figure [1](#F1){ref-type="fig"}**). High \[Na^+^\]~i~ in HF may negatively affect cardiac metabolism during rapid pacing, as elevated \[Na^+^\]~i~ has been shown to impair frequency-induced mitochondrial \[Ca^2+^\] accumulation thereby decreasing NADH/NAD^+^ redox potential, and increasing H~2~O~2~ formation in myocytes from failing hearts ([@B40]). Notably, higher oxidative stress may further exacerbate \[Na^+^\]~i~ loading by enhancing I~NaL~ through direct effects on Na~V~1.5 or secondarily by activating CaMKII ([@B70]). This suggests the interesting notion that ROS, like Na^+^, is both a cause and consequence of CaMKII activation. Not only does oxidative stress activate CaMKII directly ([@B25]), but CaMKII-induced \[Na^+^\]~i~ loading can induce an increase in ROS (**Figures [1](#F1){ref-type="fig"}** and **[3](#F3){ref-type="fig"}**). This parallels recent evidence indicating that CaMKII regulates ROS production ([@B50]; [@B58]; [@B81]). [@B37] put forward an intriguing model-based hypothesis that Na^+^ accumulation in the SERCA knock-out mouse, which occurs secondary to marked NCX upregulation and intracellular acidosis, might play a role in the development of HF in these animals. This mechanism acts by initiating a reinforcing cycle involving a mismatch between ATP supply and demand, increasingly compromised metabolism, decreased intracellular pH, and further elevation of \[Na^+^\]~i~ due to NHE, which may shift the time of transition from compensated to decompensated function.

CONCLUDING REMARKS
==================

CaMKII-dependent loss and gain of function effects on Na~V~1.5 gating are pro-arrhythmic and functionally phenocopy *SCN5A* inherited mutations causing LQTS and BrS. Analogous to BrS mutations, CaMKII-dependent loss of Na^+^ channel function and consequent reduction in Na^+^ channel availability slows cardiac conduction and increases the propensity for conduction block and re-entry. Evidence points to the I--II loop phosphorylation hot spot as a likely mediator of these loss-of-function effects. Conversely, CaMKII enhancement of I~NaL~, while not as well understood, may prolong the APD and predispose to lethal ventricular tachyarrhythmia (as in LQTS). Further study of these mechanisms may provide important advances for rational design of novel antiarrhythmic therapeutics. Additionally, experimental data and quantitative findings support the intriguing hypothesis that drugs designed to correct aberrant Na^+^ channel gating behavior, causing I~NaL~ and cellular Na^+^ loading, may act importantly by reducing Ca^2+^ overload. Growing evidence suggests that prevention of Na^+^-dependent Ca^2+^ overload is a key mechanism of action for these compounds ([@B61]; [@B79]). Inhibition of intracellular Na^+^ loading can contribute to normalizing Ca^2+^ and E~m~ homeostasis in HF, but should not be achieved at the expense of systolic function. Inhibition of CaMKII or its targets may be an attractive means of facilitating these outcomes.

AUTHOR CONTRIBUTIONS
====================

Eleonora Grandi and Anthony W. Herren wrote the article.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This study was supported by the Fondation Leducq Transatlantic CaMKII Alliance and National Institutes of Health training grant T32-GM-099608 (to Anthony W. Herren). We are grateful to Drs. Donald M. Bers and Daniel C. Bartos for critical review of the manuscript.

[^1]: Edited by: *Andrew G. Edwards, Oslo University Hospital, Norway*

[^2]: Reviewed by: *William Louch, Oslo University Hospital, Norway; Martin Vila Petroff, Centro de Investigaciones Cardiovasculares, Argentina*

[^3]: This article was submitted to Pharmacology of Ion Channels and Channelopathies, a section of the journal Frontiers in Pharmacology.
